Drugs / Anti-SARS-CoV-2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT04913779 Comparator | Jun → Nov 2021 | COVID-19, pneumonia | Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-SARS-CoV-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04913779 ↗ |
| Modality | Protein / enzyme biologic | “purified F(ab')2 fraction of equine hyperimmune serum” NCT04913779 ↗ |
| Route | Intravenous | “administered in slow intravenous infusion” NCT04913779 ↗ |